

Supplementary material

Supplementary methods

Real-Time PCR

The RNA (100 ng) extracted from TGs was reverse-transcribed using the iScript™ cDNA synthesis kit (Bio-Rad) according to the manufacturer's protocol. For relative quantification of mRNA, real time PCR was performed on Rotor Gene® Q (Qiagen). The sets of primers-probes were as follows: 18S-FW (forward): 5'-CGCGGTTCTATTTTGTGGT-3', 18S-RE (reverse): 5'-AGTCGGCATCGTTTATGGTC-3' (NCBI Ref Seq: NR_003278.3); TRPA1-FW: 5'-CAGGATGCTACGGTTTTTTCATTACT-3', TRPA1-RE: 5'-GCATGTGTCAATGTTTGGTACTTCT-3' (NCBI Ref Seq: NM_177781.4). The chosen reference gene was the 18S. The SsoAdvanced™ Universal SYBR® Green Supermix (Bio-Rad) was used for amplification, and the cycling conditions were the following: samples were heated to 95°C for 1 min followed by 40 cycles of 95°C for 10 sec, and 65°C for 20 sec. PCR reaction was carried out in triplicate.

In TGs from *Adv-Cre⁺;Trpa1^{fl/fl}* and *Adv-Cre⁻;Trpa1^{fl/fl}*, *Trpa1* was amplified and detected using the TaqMan assays (Invitrogen) (Zappia *et al.*, 2017). Relative expression of TRPA1 mRNA was calculated using the $2^{-\Delta(\Delta CT)}$ comparative method, with each gene normalized against the internal endogenous reference 18S gene.


H₂O₂ assay

TG and brainstem tissues were removed and placed into modified Krebs/HEPES buffer [mmol/l: 99.01 NaCl, 4.69 KCl, 2.50 CaCl₂, 1.20 MgSO₄, 1.03 KH₂PO₄, 25.0 NaHCO₃, 20.0 Na-HEPES, and 5.6 glucose (pH 7.4)]. Samples were minced and incubated with Amplex red (100 μM) and HRP (1 U/ml) (1h, 37°C) in modified Krebs/HEPES buffer (Landmesser *et al.*, 2003). Fluorescence excitation/emission were at 540/590 nm. H₂O₂ production was expressed as μmol/l of mg of dry tissue.

For H₂O₂ assay in cultured cells, both trigeminal neuron-SGCs mixed and SGCs-enriched primary culture were plated (5x10⁵ cells/well) in 96-well and maintained in 5% CO₂ and 95% O₂ (37°C, 48 h). The cultured medium was replaced with Krebs-Ringer phosphate (KRP) buffer [mmol/l: 2 CaCl₂, 5.4 KCl, 0.4 MgSO₄, 135 NaCl, 10 D-glucose, 10 HEPES at pH 7.4]. Both cultures were stimulated with the different stimuli added with Amplex red (50 μM) and HRP (1 U/ml) (0.5 h, room temperature, RT). Signal was


detected 3 h after exposure to the stimulus. H₂O₂ release was calculated using H₂O₂ standards and expressed as nmol/l.

Supplementary Figures



Supplementary Figure 1. (A, B) Periorbital mechanical allodynia (PMA) evoked by GTN (10 mg/kg, i.p.) in *Trpv1*^{+/+} or in *Trpv4*^{+/+} is unaffected in *Trpv1*^{-/-} or in *Trpv4*^{-/-} mice. Time-course of hind paw mechanical allodynia evoked by GTN (10 mg/kg, i.p.) in (C) C57BL/6 mice or (D) *Trpa1*^{+/+} and *Trpa1*^{-/-} mice. (E) TRPA1 antagonism by HC-030031 (HC03; 100 mg/kg, i.p.) transiently reverses GTN-evoked (10 mg/kg, i.p.) PMA in C57BL/6 mice. (F) PMA evoked by GTN (1 mg/kg, i.p.) is attenuated by (HC03 (100 mg/kg, i.p.). (G) GTN (10 mg/kg, i.p.)-evoked PMA is inhibited by A967079 (A96; 100 mg/kg, i.p.), but not by (H) capsazepine (CPZ, 4 mg/kg, i.p.) or (I) HC-067047 (HC06, 10 mg/kg, i.p.). (J) PMA evoked by subcutaneous (s.c.) injection (10 μ l/site) into the

periorbital area of AITC (10 nmol) is inhibited by s.c. HC03 (100 µg/site). (K) GTN (10 mg/kg, i.p.)-evoked PMA is inhibited by intrathecal (i.th.) A96 (10 µg). (L) Eye wiping response evoked by ocular instillation (5 µl/drop eye) of capsaicin (CPS) or AITC in RTX desensitized C57BL/6 mice. (M) Eye wiping response evoked by ocular instillation (5 µl/drop eye) of AITC in C57BL/6 mice treated (i.th.) with TRPA1 AS/MM ODN or in *Advillin-Cre⁺;Trpa1^{fl/fl}* (*Adv-Cre⁺;Trpa1^{fl/fl}*) or *Advillin-Cre⁻; Trpa1^{fl/fl}* (Control) mice. BL, baseline mechanical threshold. Veh is the vehicle of GTN. Dash (-) indicates combined vehicles of treatments. Arrows indicate time of drug administration. Error bars indicate mean ± SEM, 6-7 mice *per* group. **P* < 0.05, ***P* < 0.01, ****P* < 0.001 vs. *Trpv1^{+/+}-Veh*, *Trpv4^{+/+}- Veh*, *Trpa1^{+/+}-Veh*, Veh. #*P* < 0.05, ##*P* < 0.01, ###*P* < 0.001 vs. *Trpa1^{+/+}-GTN*, GTN, AITC, CPS; one-way or two-way ANOVA with Bonferroni post-hoc correction.



Supplementary Figure 2. (A) Representative images of staining for NOX1, NOX2 and NOX4 and neuronal (neuronal nuclei, NeuN) or satellite glial cells (glutamine synthetase, GS) in mouse trigeminal ganglion (TG) from C57BL/6 mice. (Scale bars: 100 μ m). (B, C) Periorbital mechanical allodynia (PMA) evoked by GTN (10 mg/kg, i.p.) in C57BL/6 mice is reduced by the NOX1/4 inhibitor, GKT137831 (GKT, 60 mg/kg, i.p.), and completely abated by the combination of GKT and the NOX2 selective inhibitor, gp91dstat peptide (gp91, 10 mg/kg, i.p.). Veh is the vehicle of GTN. Dash (-) indicates combined vehicles of treatments. Error bars indicate mean \pm SEM, 8 mice *per* group. *** P <0.001 vs. Veh. # P <0.05, ### P <0.001 vs. GTN; one-way ANOVA with Bonferroni post-hoc correction.

Supplementary Table 1

| Drugs | Target action | Dose | Administration route | Reference |
|----------------------|----------------------------------|---------------|----------------------|----------------------------------|
| HC-030031 | TRPA1 antagonist | 100 mg/kg | i.p. | (Eid <i>et al.</i> , 2008) |
| | | 100 µg/10 µl | s.c. | (da Costa <i>et al.</i> , 2010) |
| | | 10 µg/5 µl | i.th. | (da Costa <i>et al.</i> , 2010) |
| A967079 | TRPA1 antagonist | 100 mg/kg | i.p. | (Trevisan <i>et al.</i> , 2016) |
| | | 10 µg/5 µl | i.th. | (Wei <i>et al.</i> , 2011) |
| Capsazepine | TRPV1 antagonist | 4 mg/kg | i.p. | (Nassini <i>et al.</i> , 2011) |
| HC-067047 | TRPV4 antagonist | 10 mg/kg | i.p. | (Materazzi <i>et al.</i> , 2012) |
| Disulfiram | Aldehyde dehydrogenase inhibitor | 100 mg/kg | i.p. | (Kim <i>et al.</i> , 2010) |
| | | 10 µg/10 µl | s.c. | § |
| | | 5 µg/5 µl | i.th. | § |
| cPTIO | Nitric oxide scavenger | 0.6 mg/kg | i.p. | (Lee <i>et al.</i> , 2009) |
| | | 60 µg/10 µl | s.c. | (Nozaki <i>et al.</i> 1998) |
| | | 30 µg/5 µl | i.th. | (Chen and Pan, 2003) |
| α-lipoic acid | Antioxidant | 100 mg/kg | i.p. | (Joseph <i>et al.</i> , 2008) |
| | | 5 µg/10 µl | s.c. | (Joseph <i>et al.</i> , 2008) |
| | | 10 µg/5 µl | i.th. | § |
| PBN | Free-radical spin trap | 100 mg/kg | i.p. | (De Logu <i>et al.</i> , 2017) |
| NAC | HNE sequestering agent | 250 mg/kg | i.p. | (Rossato <i>et al.</i> , 2010) |
| | | 20 µg/10 µl | s.c. | (Rossato <i>et al.</i> , 2010) |
| | | 50 µg/5 µl | i.th. | (Rossato <i>et al.</i> , 2010) |
| L-Carnosine | HNE sequestering agent | 250 mg/kg | i.p. | (Alsheblak <i>et al.</i> , 2016) |
| Apocynin | Non selective NOX inhibitor | 100 mg/kg | i.p. | (Li <i>et al.</i> , 2013) |
| Gp91ds-tat | NOX2 inhibitor | 10 mg/kg | i.p. | (De Logu <i>et al.</i> , 2017) |
| ML171 | NOX1 inhibitor | 60 mg/kg | i.p. | (De Logu <i>et al.</i> , 2017) |
| GKT137831 | NOX1/4 inhibitor | 60 mg/kg | i.p. | (De Logu <i>et al.</i> , 2017) |
| CGRP ₈₋₃₇ | CGRP receptor antagonist | 2 µmol/kg | i.p. | (Nassini <i>et al.</i> , 2010) |
| | | 10 nmol/10 µl | s.c. | § |
| | | 5 nmol/5 µl | i.th. | (de Prado <i>et al.</i> , 2009) |
| BIBN4096BS | CGRP receptor antagonist | 1 mg/kg | i.p. | (Doods <i>et al.</i> , 2000) |
| | | 4 nmol/10 µl | s.c. | § |
| | | 1 µg/5 µl | i.th. | (Mogil <i>et al.</i> , 2005) |

§ Preliminary experiments showed that this dose did not evoke "per se" any behavioural response

Supplementary Table 2

| | Statistical test | n | P value | DEGREES OF FREEDOM & F/t values |
|----------------------------|-------------------|---------|--------------------------------------|---------------------------------|
| Fig 1 A | Two-way ANOVA | | | < 0.0001 F (24, 224)= 5.870 |
| post hoc analysis | | 8 vs. 8 | 0.5 hour GTN 10mg vs. Veh | < 0.0001 t= 7.027 |
| | | 8 vs. 8 | GTN 5mg vs. Veh | < 0.0001 t= 5.229 |
| | | 8 vs. 8 | 1 hour GTN 10 mg vs. Veh | < 0.0001 t= 8.825 |
| | | 8 vs. 8 | GTN 5mg vs. Veh | < 0.0001 t= 6.864 |
| | | 8 vs. 8 | GTN 1mg/10ml vs. Veh | 0.0447 t= 2.451 |
| | | 8 vs. 8 | 2 hours GTN 1mg vs. Veh | < 0.0001 t= 9.315 |
| | | 8 vs. 8 | GTN 5mg vs. Veh | < 0.0001 t= 6.537 |
| | | 8 vs. 8 | GTN 10mg vs. Veh | 0.0176 t= 2.778 |
| | | 8 vs. 8 | 4 hours GTN 10mg vs. Veh | < 0.0001 t= 8.661 |
| | | 8 vs. 8 | GTN 5mg vs. Veh | < 0.0001 t= 5.72 |
| | | 8 vs. 8 | 6 hours GTN 10mg vs. Veh | < 0.0001 t= 5.393 |
| | | 8 vs. 8 | GTN 5mg vs. Veh | 0.0006 t= 3.759 |
| Fig 1 B | Two tailed T test | 6 vs. 6 | GTN vs. Veh | 0.0018 t= 4.207 df= 10 |
| Fig 1 C | Two-way ANOVA | | | 0.0379 F (6, 70)= 2.377 |
| post hoc analysis | | 6 vs. 6 | 2 hours GTN WT vs. Veh WT | 0.0018 t= 4.23 |
| | | 6 vs. 6 | GTN KO vs. GTN WT | 0.0033 t= 4.067 |
| Fig 1 D | Two-way ANOVA | | | <0.0001 F (18, 196)= 7.501 |
| post hoc analysis | | 8 vs.8 | 0.5 hour GTN WT vs. Veh WT | 0.0001 t= 4.406 |
| | | 8 vs.8 | GTN KO vs. GTN WT | 0.0006 t= 3.987 |
| | | 8 vs.8 | 1 hour GTN WT vs. Veh WT | <0.0001 t= 8.603 |
| | | 8 vs.8 | GTN KO vs. GTN WT | <0.0001 t= 7.554 |
| | | 8 vs.8 | 2 hours GTN WT vs. Veh WT | <0.0001 t= 10.28 |
| | | 8 vs.8 | GTN KO vs. GTN WT | <0.0001 t= 9.022 |
| | | 8 vs.8 | 4 hours GTN WT vs. Veh WT | <0.0001 t= 8.183 |
| | | 8 vs.8 | GTN KO vs. GTN WT | <0.0001 t= 6.085 |
| | | 8 vs.8 | 6 hours GTN WT vs. Veh WT | 0.0001 t= 4.406 |
| | | 8 vs.8 | GTN KO vs. GTN WT | 0.0417 t= 2.728 |
| Fig 1 E | One-way ANOVA | | | < 0.0001 F (3, 20)= 19.74 |
| post hoc analysis | | 6 vs.6 | GTN WT vs. Veh WT | 0.0004 t= 5.027 |
| Fig 1 F left panel | One-way ANOVA | | | < 0.0001 F (4, 25)= 4.21 |
| post hoc analysis | | 6 vs. 6 | GTN vs. veh | < 0.0001 t= 6.542 |
| | | 6 vs. 6 | HC03 GTN vs. GTN | < 0.0001 t= 5.782 |
| | | 6 vs. 6 | DSF GTN vs. GTN | 0.0001 t= 5.477 |
| | | 6 vs. 6 | cPTIO GTN vs. GTN | < 0.0001 t= 5.782 |
| Fig 1 F right panel | One-way ANOVA | | | < 0.0001 F (4, 41)= 24.21 |
| post hoc analysis | | 6 vs. 6 | GTN vs. veh | < 0.0001 t= 7.327 |
| | | 6 vs. 6 | GTN HC03 vs. GTN | < 0.0001 t= 7.127 |
| Fig 1 G | One-way ANOVA | | | < 0.0001 F (3, 20)= 13.56 |
| post hoc analysis | | 6 vs. 6 | GTN vs. veh | 0.0004 t= 4.978 |
| | | 6 vs. 6 | GTN DSF vs. GTN | 0.002 t= 4.314 |

| | | | DEGREES OF FREEDOM & F/t values | |
|----------------------------|---------------|-------------------------|---------------------------------|--------------------|
| Statistical test | n | P value | | |
| Fig 2 A left panel | One-way ANOVA | | < 0.0001 | F (4, 331) = 16.97 |
| post hoc analysis | 78 vs. 53 | veh vs. 50µM | 0.0058 | t= 3.212 |
| | 78 vs.83 | veh vs. 100µM | < 0.0001 | t= 6.216 |
| | 78 vs 54 | veh vs. 300 uM | < 0.0001 | t= 6.922 |
| Fig 2 A right panel | One-way ANOVA | | 0.0061 | F (3, 144)= 4.299 |
| post hoc analysis | 29 vs. 79 | HC03 GTN vs. GTN | 0.0005 | t= 4.067 |
| Fig 2 B | One-way ANOVA | | < 0.0001 | F (3, 83)= 94.51 |
| post hoc analysis | 21 vs. 20 | GTN WT vs. Veh WT | < 0.0001 | t= 13.5 |
| | 26 vs. 21 | GTN KO vs. GTN WT | < 0.0001 | t= 14.38 |
| Fig 2 C | One-way ANOVA | | < 0.0001 | F (5, 452)= 121.4 |
| post hoc analysis | 54 vs 131 | GTN wt vs. Veh wt | < 0.0001 | t= 17.15 |
| | 77 vs.54 | GTN wt vs. GTN 3C/KQ | < 0.0001 | t= 14.32 |
| | 54 vs. 131 | Menthol wt vs. Veh wt | < 0.0001 | t= 16.44 |
| Fig 2 D left panel | One-way ANOVA | | 0.0064 | F (2, 177)= 5.204 |
| post hoc analysis | 83 vs. 47 | GTN 10 µM vs. veh | 0.0154 | t= 2.834 |
| | 83 vs. 34 | GTN 100 µM vs. veh | < 0.0001 | F (2, 145)= 35.45 |
| | | | < 0.0001 | t= 6.365 |
| Fig 2 D right panel | One-way ANOVA | | < 0.0001 | F (3, 77)= 11.62 |
| post hoc analysis | 22 vs. 20 | SNAP vs. veh | < 0.0001 | t= 5.007 |
| | 22 vs. 28 | HC03 SNAP vs. SNAP | < 0.0001 | t= 5.212 |
| | 22 vs. 21 | cPTIO SNAP vs. SNAP | 0.0037 | t= 3.351 |
| Fig 2E | Two-way ANOVA | | 0.0029 | F (12, 100)= 2.745 |
| post hoc analysis | | 0.5 hour | | |
| | 6 vs. 6 | GTN WT vs. Veh WT | 0.0003 | t= 4.272 |
| | 6 vs. 6 | GTN KO vs. GTN WT | 0.0046 | t= 3.471 |
| | | 1 hour | | |
| | 6 vs. 6 | GTN WT vs. Veh WT | < 0.0001 | t= 5.474 |
| | 6 vs. 6 | GTN KO vs. GTN WT | < 0.0001 | t= 5.741 |
| | | 2 hours | | |
| | 6 vs. 6 | GTN WT vs. Veh WT | 0.0019 | t= 3.738 |
| | 6 vs. 6 | GTN KO vs. GTN WT | 0.0165 | t= 3.071 |
| Fig 2F | Two-way ANOVA | | < 0.0001 | F (12, 140)= 7.199 |
| post hoc analysis | | 0.5 hour | | |
| | 8 vs. 8 | SNAP WT vs. Veh WT | < 0.0001 | t= 6.883 |
| | | SNAP KO vs. SNAP WT | < 0.0001 | t= 5.767 |
| | | 1 hour | | |
| | 8 vs. 8 | SNAP WT vs. Veh WT | < 0.0001 | t= 8.185 |
| | 8 vs. 8 | SNAP KO vs. SNAP WT | < 0.0001 | t= 7.999 |
| | | 2 hours | | |
| | 8 vs. 8 | SNAP WT vs. Veh WT | < 0.0001 | t= 7.069 |
| | 8 vs. 8 | SNAP KO vs. SNAP WT | < 0.0001 | t= 6.325 |
| Fig 2G | One-way ANOVA | | 0.0005 | F (5, 34)= 5.880 |
| post hoc analysis | 6 vs.6 | GTN vs. veh | 0.0032 | t= 3.576 |
| | 6 vs.6 | HC03(s.c.) GTN vs GTN | 0.0382 | t= 2.63 |
| | 6 vs.6 | HC03(i.p.) GTN vs GTN | 0.0295 | t= 2.735 |
| Fig 2 H | One-way ANOVA | | < 0.0001 | F (4, 27)= 9.380 |
| post hoc analysis | 6 vs. 6 | SNAP vs. veh | 0.0002 | t= 5.184 |
| | 6 vs. 6 | HC03(s.c.) SNAP vs SNAP | 0.0342 | t= 3.209 |
| | 6 vs. 6 | HC03(i.p.) SNAP vs SNAP | 0.0007 | t= 4.691 |
| | 8 vs.6 | cPTIO SNAP vs. SNAP | 0.0002 | t= 5.146 |

| | | | |
|---------|----------------|----------|----------|
| | 1 hour | | |
| 9 vs.6 | GTN vs. Veh | < 0.0001 | t= 6.946 |
| 9 vs.6 | NAC GTN vs GTN | 0.0074 | t= 3.893 |
| | 2 hours | | |
| 9 vs.6 | GTN vs. Veh | < 0.0001 | t= 7.785 |
| 9 vs.6 | NAC GTN vs GTN | < 0.0001 | t= 5.906 |
| | 4 hours | | |
| 6 vs. 6 | GTN vs. Veh | < 0.0001 | t= 6.004 |
| 6 vs.6 | NAC GTN vs GTN | < 0.0001 | t= 5.269 |
| | 5 hours | | |
| 9 vs.6 | GTN vs. Veh | < 0.0001 | t= 6.846 |
| 9 vs.6 | NAC GTN vs GTN | 0.0009 | t= 4.430 |
| | 6 hours | | |
| 6 vs. 6 | GTN vs. Veh | 0.0001 | t= 4.901 |
| 6 vs.6 | GTN NAC vs GTN | 0.0258 | t= 3.554 |
| | 8 hours | | |
| 9 vs.6 | GTN vs. Veh | < 0.0001 | t= 5.101 |
| 9 vs.6 | GTN NAC vs GTN | 0.0122 | t= 3.758 |

| | | | | DEGREES OF FREEDOM & F/t values | |
|-------------------|---------------|--------------------------------|----------|---------------------------------|--|
| Statistical test | n | | | P value | |
| Fig 3 A | One-way ANOVA | | | < 0.0001 F (5, 31)= 8.003 | |
| post hoc analysis | 6 vs.6 | GTN vs. Veh | 0.0003 | t= 5.006 | |
| Fig 3 B | One-way ANOVA | | | < 0.0001 F (5, 28)= 35.66 | |
| post hoc analysis | 6 vs.6 | GTN vs. Veh | < 0.0001 | t= 11.53 | |
| | 8 vs. 6 | GTN aLA vs. GTN | < 0.0001 | t= 9.124 | |
| | 6 vs.6 | GTN PBN vs. GTN | < 0.0001 | t= 9.732 | |
| | 7 vs.6 | NAC GTN vs. GTN | < 0.0001 | t= 5.798 | |
| | 6 vs.6 | Carn GTN vs. GTN | < 0.0001 | t= 5.948 | |
| Fig 3 C | One-way ANOVA | | | < 0.0001 F (5, 32)= 15.80 | |
| post hoc analysis | 6 vs.6 | GTN vs. Veh | < 0.0001 | t= 6.063 | |
| | 7 vs.6 | NAC GTN vs. GTN | 0.0215 | t= 3.073 | |
| | 6 vs.6 | Carn GTN vs. GTN | 0.0003 | t= 4.653 | |
| Fig 3 D | One-way ANOVA | | | < 0.0001 F (3, 28)= 67.63 | |
| post hoc analysis | 8 vs.8 | GTN vs. Veh | < 0.0001 | t= 12.48 | |
| Fig 3 E | One-way ANOVA | | | < 0.0001 F (3, 28)= 35.89 | |
| post hoc analysis | 8 vs.8 | GTN vs. Veh | < 0.0001 | t= 8.873 | |
| Fig 3 F | Two-way ANOVA | | | < 0.0001 F (14, 124)= 4.197 | |
| post hoc analysis | | 1 hour | | | |
| | 6 vs.6 | GTN vs. Veh | 0.0008 | t= 4.311 | |
| | 6 vs.6 | GTN NAC vs Veh | < 0.0001 | t= 5.127 | |
| | | 2 hours | | | |
| | 6 vs.6 | GTN vs. Veh | < 0.0001 | t= 6.292 | |
| | 6 vs.6 | GTN NAC vs Veh | < 0.0001 | t= 6.409 | |
| | | 4 hours | | | |
| | 6 vs.6 | GTN vs. Veh | < 0.0001 | t= 5.826 | |
| | 6 vs.6 | GTN NAC vs Veh | < 0.0001 | t= 5.826 | |
| | | 5 hours | | | |
| | 6 vs.6 | GTN vs. Veh | < 0.0001 | t= 4.894 | |
| | 6 vs.6 | GTN NAC vs Veh | < 0.0001 | t= 5.481 | |
| | | 6 hours | | | |
| | 6 vs.6 | GTN vs. Veh | 0.0019 | t= 4.078 | |
| | | GTN NAC vs Veh | < 0.0001 | t= 4.983 | |
| | | 8 hours | | | |
| | 6 vs.6 | GTN vs. Veh | 0.0246 | t= 3.029 | |
| | | GTN NAC vs Veh | 0.0246 | t= 3.363 | |
| Fig 3 G | One-way ANOVA | | | < 0.0001 F (5, 35)= 9.520 | |
| post hoc analysis | 6 vs.6 | GTN vs. Veh | 0.0241 | t= 2.924 | |
| | 7 vs. 6 | HC03 GTN vs. GTN | 0.0316 | t= 2.817 | |
| | 7 vs. 6 | DSF GTN vs. GTN | 0.0023 | t= 3.793 | |
| | 9 vs.6 | cPTIO GTN vs. GTN | 0.0002 | t= 4.575 | |
| Fig 3 H | One-way ANOVA | | | < 0.0001 F (5, 42) = 41.13 | |
| post hoc analysis | 8 vs.8 | GTN vs. Veh | < 0.0001 | t= 9.442 | |
| | 8 vs.8 | GTN HC03 vs. GTN | < 0.0001 | t= 8.534 | |
| | 8 vs.8 | GTN aLA vs. GTN | < 0.0001 | t= 8.171 | |
| Fig 3 I | Two-way ANOVA | | | < 0.0001 F (24, 192)= 5.932 | |
| post hoc analysis | 6 vs.6 | 0.5 hour GTN vs. Veh | < 0.0001 | t= 5.098 | |

| | | | |
|---------|----------------|----------|----------|
| | 1 hour | | |
| 9 vs.6 | GTN vs. Veh | < 0.0001 | t= 6.946 |
| 9 vs.6 | NAC GTN vs GTN | 0.0074 | t= 3.893 |
| | 2 hours | | |
| 9 vs.6 | GTN vs. Veh | < 0.0001 | t= 7.785 |
| 9 vs.6 | NAC GTN vs GTN | < 0.0001 | t= 5.906 |
| | 4 hours | | |
| 6 vs. 6 | GTN vs. Veh | < 0.0001 | t= 6.004 |
| 6 vs.6 | NAC GTN vs GTN | < 0.0001 | t= 5.269 |
| | 5 hours | | |
| 9 vs.6 | GTN vs. Veh | < 0.0001 | t= 6.846 |
| 9 vs.6 | NAC GTN vs GTN | 0.0009 | t= 4.430 |
| | 6 hours | | |
| 6 vs. 6 | GTN vs. Veh | 0.0001 | t= 4.901 |
| 6 vs.6 | GTN NAC vs GTN | 0.0258 | t= 3.554 |
| | 8 hours | | |
| 9 vs.6 | GTN vs. Veh | < 0.0001 | t= 5.101 |
| 9 vs.6 | GTN NAC vs GTN | 0.0122 | t= 3.758 |

| | | | | DEGREES OF FREEDOM & F/t values | |
|-------------------|-------------------|---------------------|---------------------------|---------------------------------|--------------|
| Statistical test | n | P value | | | |
| Fig 4 A | One-way ANOVA | H2O2 level | < 0.0001 F (6, 36)= 10.66 | | |
| post hoc analysis | | 1 hour | | | |
| | 6 vs. 6 | GTN vs. BL | 0.0227 | t= | 3.094 |
| | | 2 hours | | | |
| | 6 vs. 6 | GTN vs. BL | < 0.0001 | t= | 6.38 |
| | | 3 hours | | | |
| | 6 vs. 6 | GTN vs. BL | 0.0059 | t= | 3.586 |
| | | HNE level | < 0.0001 F (5, 18)= 37.64 | | |
| post hoc analysis | 4 vs.4 | GTN 4h vs. GTN 0.5h | < 0.0001 | t= | 8.475 |
| | 4 vs.4 | GTN 6h vs. GTN 0.5h | < 0.0001 | t= | 10.53 |
| Fig 4 C | One-way ANOVA | H2O2 level | < 0.0001 F (5, 26)= 39.14 | | |
| post hoc analysis | 4 vs. 4 | GTN vs. Veh | < 0.0001 | t= | 10.58 |
| | 6 vs.4 | cPTIO GTN vs. GTN | < 0.0001 | t= | 11.95 |
| | 6 vs.4 | DSF GTN vs. GTN | < 0.0001 | t= | 11.48 |
| | 6 vs.4 | a-LA GTN vs. GTN | < 0.0001 | t= | 10.04 |
| | 6 vs.4 | HC03 GTN vs. GTN | < 0.0001 | t= | 11.99 |
| Fig 4 D | One-way ANOVA | HNE level | 0.0003 F (4, 23)= 8.122 | | |
| post hoc analysis | 6 vs.4 | GTN cPTIO vs. GTN | 0.0013 | t= | 4.208 |
| | 6 vs.4 | GTN aLA vs. GTN | 0.0002 | t= | 4.974 |
| | 6 vs.4 | GTN NAC vs. GTN | 0.0001 | t= | 5.165 |
| | 6 vs.4 | GTN HC03 vs. GTN | 0.0022 | t= | 4.017 |
| Fig 4 E | One-way ANOVA | H2O2 level | < 0.0001 F (3, 20)= 29.14 | | |
| post hoc analysis | 6 vs.6 | GTN wt vs. Veh wt | < 0.0001 | t= | 7.718 |
| | 6 vs.6 | GTN wt vs. GTN ko | < 0.0001 | t= | 7.532 |
| | Two tailed T test | HNE level | | | |
| | 6 vs.6 | GTN wt vs. GTN ko | 0.0009 | t= | 4.622 df= 10 |

| | | | DEGREES OF FREEDOM & F/t values | |
|-------------------|-------------------|-----------------------|---------------------------------|-----------------|
| Statistical test | n | P value | | |
| Fig 5 B | Two-way ANOVA | | < 0.0001 F (12, 112) = 3.908 | |
| | | 0.5 hour | | |
| post hoc analysis | 6 vs. 6 | GTN vs. Veh | 0.0006 | t= 4.349 |
| | 7 vs. 6 | RTX GTN vs. GTN | < 0.0001 | t= 4.851 |
| | | 1 hour | | |
| | 6 vs. 6 | GTN vs. Veh | < 0.0001 | t= 4.892 |
| | 7 vs. 6 | RTX GTN vs. GTN | < 0.0001 | t= 5.303 |
| | | 2 hours | | |
| | 6 vs. 6 | GTN vs. Veh | < 0.0001 | t= 5.762 |
| | 7 vs. 6 | RTX GTN vs. GTN | < 0.0001 | t= 6.205 |
| | | 4 hours | | |
| | 6 vs. 6 | GTN vs. Veh | 0.0001 | t= 4.784 |
| | 7 vs. 6 | RTX GTN vs. GTN | < 0.0001 | t= 5.190 |
| | | 6 hours | | |
| | 6 vs. 6 | GTN vs. Veh | 0.0019 | t= 2.718 |
| | 7 vs. 6 | RTX GTN vs. GTN | 0.0165 | t= 2.595 |
| | One-way ANOVA | H2O2 level | < 0.0001 F (2, 15)= 52.92 | |
| post hoc analysis | 6 vs. 6 | GTN vs Veh RTX | < 0.0001 | t= 9.360 |
| | 6 vs. 6 | GTN RTX vs GTN | < 0.0001 | t= 8.377 |
| Fig 5 C | One-way ANOVA | H2O2 level | < 0.0001 F (5, 55)= 87.18 | |
| post hoc analysis | 8 vs. 21 | Ca2+-free GTN vs. GTN | < 0.0001 | t= 14.81 |
| | 8 vs. 21 | CPS des GTN vs. GTN | < 0.0001 | t= 15.72 |
| | 6 vs. 21 | HC03 GTN vs. GTN | < 0.0001 | t= 13.47 |
| | Two tailed T test | | | |
| | 6 vs. 8 | HC03 AITC vs. AITC | < 0.0001 | t= 12.16 df= 12 |
| | Two tailed T test | | | |
| | 8 vs. 8 | HC03 SNAP vs. SNAP | < 0.0001 | t= 30.14 df= 14 |
| Fig 5 E | Two tailed T test | mRNA level | | |
| | 6 vs. 8 | AS vs. MM | < 0.0001 | t= 12.16 df= 12 |
| | Two-way ANOVA | | < 0.0001 F (18, 151)= 5.566 | |
| | | 0.5 hour | | |
| post hoc analysis | 7 vs. 6 | MM GTN vs. MM Veh | < 0.0001 | t= 6.310 |
| | 7 vs. 7 | AS GTN vs. MM GTN | < 0.0001 | t= 4.854 |
| | | 1 hour | | |
| | 7 vs. 6 | MM GTN vs. MM Veh | < 0.0001 | t= 7.545 |
| | 7 vs. 7 | AS GTN vs. MM GTN | < 0.0001 | t= 6.996 |
| | | 2 hours | | |
| | 6 vs. 6 | MM GTN vs. MM Veh | < 0.0001 | t= 8.093 |
| | 7 vs. 6 | AS GTN vs. MM GTN | < 0.0001 | t= 7.995 |
| | | 4 hours | | |
| | 6 vs. 6 | MM GTN vs. MM Veh | < 0.0001 | t= 6.859 |
| | 7 vs. 6 | AS GTN vs. MM GTN | < 0.0001 | t= 5.761 |
| | | 6 hours | | |
| | 6 vs. 6 | MM GTN vs. MM Veh | < 0.0001 | t= 5.350 |
| | 7 vs. 6 | AS GTN vs. MM GTN | < 0.0001 | t= 5.075 |
| | One-way ANOVA | H2O2 level | < 0.0001 F (3, 20)= 20.11 | |
| post hoc analysis | 6 vs.6 | GTN MM vs. Veh MM | < 0.0001 | t= 6.497 |
| | 6 vs.6 | GTN AS vs. GTN MM | < 0.0001 | t= 6.264 |
| Fig 5 F | Two tailed T test | mRNA level | | |
| | 6 vs. 8 | AS vs. MM | < 0.0001 | t= 9.625 df= 6 |

| Two-way ANOVA | | < 0.0001 F (18, 140)= 3.568 | |
|-------------------|----------------------------|-----------------------------|---------------------------|
| post hoc analysis | | 0.5 hour | |
| | 7 vs. 6 | Control GTN vs.Control Veh | 0.0002 t= 4.274 |
| | 7 vs. 7 | Adv-cre GTN vs Control GTN | < 0.0001 t=5.280 |
| | | 1 hour | |
| | 7 vs. 6 | Control GTN vs.Control Veh | < 0.0001 t= 4.651 |
| | 7 vs. 7 | Adv-cre GTN vs Control GTN | < 0.0001 t= 5.280 |
| | | 2 hours | |
| | 6 vs. 6 | Control GTN vs.Control Veh | < 0.0001 t= 6.034 |
| | 7 vs. 6 | Adv-cre GTN vs Control GTN | < 0.0001 t= 6.411 |
| | | 4 hours | |
| | 6 vs. 6 | Control GTN vs.Control Veh | < 0.0001 t= 5.280 |
| | 7 vs. 6 | Adv-cre GTN vs Control GTN | < 0.0001 t= 5.531 |
| | 6 hours | | |
| 6 vs. 6 | Control GTN vs.Control Veh | 0.0002 t= 4.274 | |
| 7 vs. 6 | Adv-cre GTN vs Control GTN | < 0.0001 t= 4.902 | |
| | One-way ANOVA | | |
| post hoc analysis | | H2O2 level | < 0.0001 F (3, 20)= 12.29 |
| | 6 vs.6 | Control GTN vs.Control Veh | 0.004 t= 4.025 |
| | 6 vs.6 | Adv-cre GTN vs Control GTN | 0.0002 t= 5.368 |

| | | | DEGREES OF FREEDOM & F/t values | |
|-------------------|---------|------------------------|---------------------------------|------------------|
| Statistical test | n | P value | | |
| Fig 6 B | | One-way ANOVA | 0.0002 | F (4, 27)= 8.044 |
| post hoc analysis | 7 vs. 7 | GTN vs. Veh | < 0.0001 | t= 5.430 |
| Fig 6 C | | One-way ANOVA | < 0.0001 | F (5, 42)= 32.22 |
| post hoc analysis | 8 vs. 8 | GTN vs. Veh | < 0.0001 | t= 10.20 |
| | 8 vs. 8 | Apo GTN vs. GTN | < 0.0001 | t= 9.238 |
| | 8 vs. 8 | gp91 GTN vs. GTN | < 0.0001 | t= 5.196 |
| | 8 vs. 8 | ML171 GTN vs. GTN | 0.0002 | t= 6.543 |
| | 8 vs. 8 | gp91+ML171 GTN vs. GTN | < 0.0001 | t= 10.58 |

| | | | DEGREES OF FREEDOM & F/t values | |
|---------------------|---------|-------------------------------------|---------------------------------|----------|
| Statistical test | n | P value | | |
| Fig 7 A left panel | | One-way ANOVA | < 0.0001 F (3, 25)= 16.46 | |
| post hoc analysis | 8 vs.6 | GTN vs. veh | < 0.0001 | t= 6.971 |
| | 7 vs.8 | BIBN GTN vs GTN | 0.0449 | t= 2.91 |
| Fig 7 A right panel | | One-way ANOVA | < 0.0001 F (3, 25) = 51.55 | |
| post hoc analysis | 8 vs.6 | GTN vs. veh | < 0.0001 | t= 12.29 |
| | 7 vs.8 | GTN BIBN vs GTN | < 0.0001 | t= 7.126 |
| | 8 vs.8 | GTN CGRP837 vs. GTN | < 0.0001 | t= 6.639 |
| Fig 7 B left panel | | One-way ANOVA | < 0.0001 F (3, 20)= 23.27 | |
| post hoc analysis | 6 vs.6 | GTN vs. veh | < 0.0001 | t= 6.635 |
| Fig 7 B right panel | | One-way ANOVA | < 0.0001 F (3, 17)= 29.24 | |
| post hoc analysis | 6 vs.6 | GTN vs. veh | < 0.0001 | t= 7.932 |
| Fig 7 C | | Two-way ANOVA | < 0.0001 F (15, 168)= 6.653 | |
| post hoc analysis | 8 vs. 8 | 0.5 hour CGRP 5µg vs. Veh | < 0.0001 | t= 5.364 |
| | 8 vs. 8 | 1 hour CGRP 5µg vs. Veh | < 0.0001 | t= 6.954 |
| | 8 vs. 8 | 2 hours GTN 5 µg vs. Veh | < 0.0001 | t= 8.146 |
| | 8 vs. 8 | 4 hours GTN 5 µg vs. Veh | < 0.0001 | t= 5.166 |
| Fig 7 D | | One-way ANOVA | 0.0014 F (3, 25)= 7.034 | |
| post hoc analysis | 8 vs.7 | CGRP vs. Veh | 0.0007 | t= 4.316 |
| | 8 vs.7 | CGRP8-37 CGRP vs. CGRP | 0.0462 | t= 2.594 |
| | 8 vs.7 | BIBN CGRP vs. CGRP | 0.008 | t= 3.335 |
| Fig 7 E left panel | | One-way ANOVA | < 0.0001 F (3, 20)= 25.53 | |
| post hoc analysis | 6 vs.6 | GTN vs. Veh | < 0.0001 | t= 6.685 |
| Fig 7 E right panel | | One-way ANOVA | < 0.0001 F (3, 21)= 26.56 | |
| post hoc analysis | 6 vs.6 | GTN vs. veh | < 0.0001 | t= 8.770 |
| | 7 vs.6 | GTN BIBN vs GTN | < 0.0001 | t= 5.957 |
| | 6 vs.6 | GTN CGRP837 vs. GTN | 0.0003 | t= 5.102 |
| Fig 7 F | | One-way ANOVA | < 0.0001 F (3, 20)= 39.98 | |
| post hoc analysis | 6 vs.6 | GTN vs. Veh | < 0.0001 | t= 8.322 |
| | 6 vs.6 | BIBN GTN vs Veh | < 0.0001 | t= 7.077 |

| | Statistical test | n | P value | DEGREES OF FREEDOM & F/t values |
|----------------------|----------------------|-------------------|----------|---------------------------------|
| Suppl Fig 1 A | Two-way ANOVA | | | < 0.0001 F (18, 140)= 5.563 |
| post hoc analysis | 0.5 hour | | | |
| | 6 vs. 6 | GTN WT vs. Veh WT | < 0.0001 | t= 5.436 |
| | 6 vs. 6 | GTN KO vs. Veh WT | < 0.0001 | t= 5.310 |
| | 1 hour | | | |
| | 6 vs. 6 | GTN WT vs. Veh WT | < 0.0001 | t= 6.574 |
| | 6 vs. 6 | GTN KO vs. Veh WT | < 0.0001 | t= 6.447 |
| | 2 hours | | | |
| | 6 vs. 6 | GTN WT vs. Veh WT | < 0.0001 | t= 6.447 |
| | 6 vs. 6 | GTN KO vs. Veh WT | < 0.0001 | t= 6.574 |
| | 4 hours | | | |
| | 6 vs. 6 | GTN WT vs. Veh WT | < 0.0001 | t= 6.700 |
| | 6 vs. 6 | GTN KO vs. Veh WT | < 0.0001 | t= 6.700 |
| | 6 hours | | | |
| | 6 vs. 6 | GTN WT vs. Veh WT | < 0.0001 | t= 5.562 |
| 6 vs. 6 | GTN KO vs. Veh WT | < 0.0001 | t= 6.447 | |
| Suppl Fig 1 B | Two-way ANOVA | | | < 0.0001 F (18, 140)= 3.628 |
| post hoc analysis | 0.5 hour | | | |
| | 6 vs. 6 | GTN WT vs. Veh WT | 0.0031 | t= 3.900 |
| | 6 vs. 6 | GTN KO vs. Veh WT | 0.0067 | t= 3.689 |
| | 1 hour | | | |
| | 6 vs. 6 | GTN WT vs. Veh WT | < 0.0001 | t= 5.270 |
| | 6 vs. 6 | GTN KO vs. Veh WT | 0.0006 | t= 4.322 |
| | 2 hours | | | |
| | 6 vs. 6 | GTN WT vs. Veh WT | < 0.0001 | t= 6.008 |
| | 6 vs. 6 | GTN KO vs. Veh WT | < 0.0001 | t= 5.060 |
| | 4 hours | | | |
| | 6 vs. 6 | GTN WT vs. Veh WT | 0.0021 | t= 4.006 |
| | 6 vs. 6 | GTN KO vs. Veh WT | 0.0286 | t= 3.268 |
| | 6 hours | | | |
| | 6 vs. 6 | GTN WT vs. Veh WT | 0.0403 | t= 3.162 |
| 6 vs. 6 | GTN KO vs. Veh WT | 0.0286 | t= 3.268 | |
| Suppl Fig 1 C | Two-way ANOVA | | | < 0.0001 F (6, 70)= 6.154 |
| post hoc analysis | 0.5 hour | | | |
| | 6 vs. 6 | GTN 10mg vs. Veh | 0.0022 | t= 3.789 |
| | 1 hour | | | |
| | 6 vs. 6 | GTN 10mg vs. Veh | < 0.0001 | t= 5.92 |
| | 2 hours | | | |
| | 6 vs. 6 | GTN 10mg vs. Veh | < 0.0001 | t= 6.204 |
| | 4 hours | | | |
| | 6 vs. 6 | GTN 10mg vs. Veh | 0.0002 | t= 4.452 |
| 6 hours | | | | |
| 6 vs. 6 | GTN 10mg vs. Veh | 0.0022 | t= 3.789 | |
| Suppl Fig 1 D | Two-way ANOVA | | | 0.0001 F (18, 141)= 3.010 |
| post hoc analysis | 2 hours | | | |
| | 6 vs. 6 | GTN WT vs. Veh WT | < 0.0001 | t= 5.349 |
| | 6 vs. 6 | GTN KO vs. GTN WT | 0.0007 | t= 4.442 |
| | 4 hours | | | |
| | 6 vs. 6 | GTN WT vs. Veh WT | 0.0013 | t= 4.298 |
| | 6 vs. 6 | GTN KO vs. GTN WT | 0.0371 | t= 3.391 |
| | 6 hours | | | |
| | 6 vs. 6 | GTN WT vs. Veh WT | 0.0006 | t= 4.489 |
| | 6 vs. 6 | GTN KO vs. GTN WT | 0.0392 | t= 3.375 |
| | Suppl Fig 1 E | One-way ANOVA | | |
| post hoc analysis | 4 hours | | | |
| | 6 vs.6 | GTN vs. veh | < 0.0001 | t= 7.261 |
| | 6 vs.6 | GTN HC03 vs. GTN | 0.0002 | t= 5.410 |
| post hoc analysis | One-way ANOVA | | | 0.0011 F (2, 15)= 11.02 |
| | 5 hours | | | |
| | 6 vs.6 | GTN vs. veh | 0.0019 | t= 4.287 |
| | 6 vs.6 | GTN HC03 vs. GTN | 0.0052 | t= 3.8 |

| | | | | |
|---------------------------------|---------------|------------------------------|----------|------------------|
| | One-way ANOVA | | 0.0011 | F (2, 15)= 11.16 |
| | | 6 hours | | |
| post hoc analysis | 6 vs.6 | GTN vs. veh | 0.001 | t= 4.601 |
| | 6 vs.6 | GTN HC03 vs. GTN | 0.0167 | t= 3.233 |
| Suppl Fig 1 F | One-way ANOVA | | 0.0002 | F (2, 16)= 15.37 |
| post hoc analysis | 7 vs.6 | GTN vs. veh | 0.0005 | t= 4.838 |
| | 7 vs.6 | HC03 GTN vs. GTN | 0.0008 | t= 4.637 |
| Suppl Fig 1G left panel | One-way ANOVA | | < 0.0001 | F (2, 15)= 19.68 |
| post hoc analysis | 6 vs.6 | GTN vs. veh | 0.0002 | t= 5.578 |
| | 6 vs.6 | A96 GTN vs. GTN | 0.0003 | t= 5.276 |
| Suppl Fig 1G right panel | One-way ANOVA | | < 0.0001 | F (2, 15)= 34.16 |
| post hoc analysis | 6 vs.6 | GTN vs. veh | < 0.0001 | t= 7.453 |
| | 6 vs.6 | GTN A96 vs. GTN | < 0.0001 | t= 6.821 |
| Suppl Fig 1H | One-way ANOVA | | < 0.0001 | F (2, 17)= 36.13 |
| post hoc analysis | 6 vs.6 | GTN vs. veh | < 0.0001 | t= 7.915 |
| Suppl Fig 1I | One-way ANOVA | | < 0.0001 | F (2, 16)= 21.02 |
| post hoc analysis | 7 vs.6 | GTN vs. veh | 0.0001 | t=5.616 |
| Suppl Fig 1J | One-way ANOVA | | 0.035 | F (2, 16)= 8.239 |
| post hoc analysis | 7 vs.6 | AITC vs. veh | 0.0042 | t= 3.853 |
| | 7 vs.6 | HC03 AITC vs. AITC | 0.0306 | t= 2.911 |
| Suppl Fig 1K left panel | One-way ANOVA | | 0.016 | F (2, 15)= 5.457 |
| post hoc analysis | 6 vs.6 | GTN vs. veh | 0.0172 | t= 3.020 |
| | 6 vs.6 | A96 GTN vs. GTN | 0.035 | t= 2.669 |
| Suppl Fig 1K right panel | One-way ANOVA | | 0.0007 | F (2, 15)= 12.18 |
| post hoc analysis | 6 vs.6 | GTN vs. veh | 0.0014 | t= 4.234 |
| | 6 vs.6 | GTN A96 vs. GTN | 0.0012 | t= 4.312 |
| Suppl Fig 1L left panel | One-way ANOVA | | < 0.0001 | F (3, 20)= 28.32 |
| post hoc analysis | 6 vs.6 | CAPS vs. Veh | < 0.0001 | t= 7.676 |
| | 6 vs.6 | RTX CPS vs. Veh RTX CPS | < 0.0001 | t= 7.217 |
| Suppl Fig 1L right panel | One-way ANOVA | | < 0.0001 | F (3, 20)= 17.52 |
| post hoc analysis | 6 vs.6 | AITC vs. Veh | < 0.0001 | t= 6.099 |
| | 6 vs.6 | RTX AITC vs. Veh RTX AITC | 0.0003 | t= 5.090 |
| Suppl Fig 1M left panel | One-way ANOVA | | < 0.0001 | F (3, 20)= 91.23 |
| post hoc analysis | 6 vs.6 | MM AITC vs. MM veh | < 0.0001 | t= 13.56 |
| | 6 vs.6 | AS AITC vs. MM AITC | < 0.0001 | t= 12.47 |
| Suppl Fig 1M right panel | One-way ANOVA | | 0.0018 | F (3, 20)= 7.191 |
| post hoc analysis | 6 vs.6 | AITC control vs. Veh control | 0.0043 | t= 3.989 |
| | 6 vs.6 | AITC Adv-cre vs AITC control | 0.0258 | t= 3.220 |

| | | | DEGREES OF FREEDOM & F/t values | |
|----------------------|---------|----------------------|---------------------------------|----------|
| Statistical test | n | P value | | |
| Suppl Fig 2 B | | One-way ANOVA | < 0.0001 F (2, 21) = 42.56 | |
| post hoc analysis | 8 vs. 8 | GTN vs. veh | < 0.0001 | t= 9.007 |
| | 8 vs. 8 | GTN GKT vs. GTN | 0.0339 | t= 2.771 |
| Suppl Fig 2 C | | One-way ANOVA | < 0.0001 F (2, 21) = 186.0 | |
| post hoc analysis | 8 vs. 8 | GTN vs. veh | < 0.0001 | t= 16.37 |
| | 8 vs. 8 | GTN GKT+gp91 vs. GTN | < 0.0001 | t= 17.02 |

References

- Alsheblak MM, Elsherbiny NM, El-Karef A, El-Shishtawy MM. Protective effects of L-carnosine on CCl₄ -induced hepatic injury in rats. *Eur Cytokine Netw* 2016; 27:6-15.
- Chen SR, Pan HL. Spinal nitric oxide contributes to the analgesic effect of intrathecal [d-pen²,d-pen⁵]-enkephalin in normal and diabetic rats. *Anesthesiology* 2003; 98:217-22.
- Chen Y, Kanju P, Fang Q, Lee SH, Parekh PK, Lee W, *et al.* TRPV4 is necessary for trigeminal irritant pain and functions as a cellular formalin receptor. *Pain* 2014; 155:2662-72.
- da Costa DS, Meotti FC, Andrade EL, Leal PC, Motta EM, Calixto JB. The involvement of the transient receptor potential A1 (TRPA1) in the maintenance of mechanical and cold hyperalgesia in persistent inflammation. *Pain* 2010; 148:431-7.
- De Logu F, Nassini R, Materazzi S, Carvalho Goncalves M, Nosi D, Rossi Degl'Innocenti D, *et al.* Schwann cell TRPA1 mediates neuroinflammation that sustains macrophage-dependent neuropathic pain in mice. *Nat Commun* 2017; 8:1887.
- Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W, *et al.* Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. *Br J Pharmacol* 2000; 129:420-3.
- Eid SR, Crown ED, Moore EL, Liang HA, Choong KC, Dima S, *et al.* HC-030031, a TRPA1 selective antagonist, attenuates inflammatory- and neuropathy-induced mechanical hypersensitivity. *Mol Pain* 2008; 4:48.
- Glowka TR, Steinebach A, Stein K, Schwandt T, Lysson M, Holzmann B, *et al.* The novel CGRP receptor antagonist BIBN4096BS alleviates a postoperative intestinal inflammation and prevents postoperative ileus. *Neurogastroenterol Motil* 2015; 27:1038-49.
- Jeong BK, Song JH, Jeong H, Choi HS, Jung JH, Hahm JR, *et al.* Effect of alpha-lipoic acid on radiation-induced small intestine injury in mice. *Oncotarget* 2016; 7:15105-17.

- Jiang JX, Chen X, Serizawa N, Szyndralewicz C, Page P, Schroder K, *et al.* Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. *Free Radic Biol Med* 2012; 53:289-96.
- Joseph EK, Chen X, Bogen O, Levine JD. Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. *J Pain* 2008; 9:463-72.
- Kim AK, Souza-Formigoni ML. Disulfiram impairs the development of behavioural sensitization to the stimulant effect of ethanol. *Behav Brain Res* 2010; 207:441-6.
- Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, *et al.* Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. *J Clin Invest* 2003; 111:1201-9.
- Lee EJ, Hung YC, Chen HY, Wu TS, Chen TY. Delayed treatment with carboxy-PTIO permits a 4-h therapeutic window of opportunity and prevents against ischemia-induced energy depletion following permanent focal cerebral ischemia in mice. *Neurochem Res* 2009; 34:1157-66.
- Li YQ, Li XB, Guo SJ, Chu SL, Gao PJ, Zhu DL, *et al.* Apocynin attenuates oxidative stress and cardiac fibrosis in angiotensin II-induced cardiac diastolic dysfunction in mice. *Acta Pharmacol Sin* 2013; 34:352-9.
- Marquez de Prado B, Hammond DL, Russo AF. Genetic enhancement of calcitonin gene-related Peptide-induced central sensitization to mechanical stimuli in mice. *J Pain* 2009; 10:992-1000.
- Materazzi S, Fusi C, Benemei S, Pedretti P, Patacchini R, Nilius B, *et al.* TRPA1 and TRPV4 mediate paclitaxel-induced peripheral neuropathy in mice via a glutathione-sensitive mechanism. *Pflugers Arch* 2012; 463:561-9.
- Mogil JS, Miermeister F, Seifert F, Strasburg K, Zimmermann K, Reinold H, *et al.* Variable sensitivity to noxious heat is mediated by differential expression of the CGRP gene. *Proc Natl Acad Sci U S A* 2005; 102:12938-43.
- Nassini R, Materazzi S, Andre E, Sartiani L, Aldini G, Trevisani M, *et al.* Acetaminophen, via its reactive metabolite N-acetyl-p-benzo-quinoneimine and transient receptor potential ankyrin-1 stimulation, causes neurogenic inflammation in the airways and other tissues in rodents. *Faseb J* 2010; 24:4904-16.
- Nassini R, Gees M, Harrison S, De Siena G, Materazzi S, Moretto N, *et al.* Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. *Pain* 2011; 152:1621-31.

- Nozaki-Taguchi N, Yamamoto T. Involvement of nitric oxide in peripheral antinociception mediated by kappa- and delta-opioid receptors. *Anesth Analg* 1998; 87:388-93.
- Rossato MF, Velloso NA, de Oliveira Ferreira AP, de Mello CF, Ferreira J. Spinal levels of nonprotein thiols are related to nociception in mice. *J Pain* 2010; 11:545-54.
- Trevisan G, Benemei S, Materazzi S, De Logu F, De Siena G, Fusi C, *et al.* TRPA1 mediates trigeminal neuropathic pain in mice downstream of monocytes/macrophages and oxidative stress. *Brain* 2016; 139:1361-77.
- Wei H, Koivisto A, Saarnilehto M, Chapman H, Kuokkanen K, Hao B, *et al.* Spinal transient receptor potential ankyrin 1 channel contributes to central pain hypersensitivity in various pathophysiological conditions in the rat. *Pain* 2011; 152:582-91.
- Yilmaz Z, Kalaz EB, Aydin AF, Soluk-Tekkesin M, Dogru-Abbasoglu S, Uysal M, *et al.* The effect of carnosine on methylglyoxal-induced oxidative stress in rats. *Arch Physiol Biochem* 2017; 123:192-98.
- Zappia KJ, O'Hara CL, Moehring F, Kwan KY, Stucky CL. Sensory Neuron-Specific Deletion of TRPA1 Results in Mechanical Cutaneous Sensory Deficits. *eNeuro* 2017; 4:0069-16.